What are the key improvements for environment and health from the agreed package?
Authorisation: The main benefit of REACH relates to a stricter authorisation system. Prior to applying for authorisation all companies will have to analyse alternatives. If they identify a suitable alternative, they will have to submit a substitution plan. If no suitable alternatives are identified, they will have to inform on relevant research and development activities, if any.
All persistent and bio-accumulative substances (PBTs and vPvBs) can only be authorised if no suitable substitute is available and if it is demonstrated that the socio-economic benefits from the particular use of the substance outweigh the risks to human health and the environment. The Commission will review whether endocrine disruptors should be subjected to the same strict conditions after 6 years from entry into force of REACH.
The criteria for identifying persistent and bio-accumulative substances (PBTs and vPvBs) will be reviewed and updated by the Commission within 18 months of entry into force of REACH.
Information flow: REACH will make more information available to consumers about the presence of substances of very high concern in articles.
